Prophylactic Protein Free Synthetic Surfactant for Preventing Morbidity and Mortality in Preterm Infants

Overview

Journal Cochrane Database Syst Rev

Publisher Wiley

Specialties General Medicine
Health Services

Date 2010 Jan 22

PMID 20091513

Citations 37

Authors

Roger Soll

Eren Ozek

Affiliations

Soon will be listed here.

Abstract

Background: Respiratory distress syndrome (RDS) is caused by a deficiency or dysfunction of pulmonary surfactant. A variety of surfactant products including protein free synthetic surfactant have been developed and tested in the prevention and treatment of RDS.

Objectives: To assess the effect of prophylactic administration of protein free synthetic surfactant (SS) on mortality, chronic lung disease and other morbidities associated with prematurity in preterm newborns at risk for developing RDS. Subgroup analysis were planned according to the degree of prematurity, surfactant product and dosage schedule.

Search Strategy: Searches were made of the The Cochrane Library, MEDLINE, OVID, EMBASE, CINAHL from 1966 to 2009. In addition, previous reviews including cross references and abstracts from the Society for Pediatric Research were searched. No language restrictions were applied.

Selection Criteria: Randomized and quasi-randomized controlled trials that compared the effect of protein free SS administered to high risk preterm newborns at or shortly after birth in order to prevent RDS, mortality and complications of prematurity.

Data Collection And Analysis: Data regarding clinical outcomes was excerpted from the clinical trials by the reviewers. Data were analyzed according to the standards of the Cochrane Neonatal Review Group.

Main Results: Studies of prophylactic administration of protein free SS note a variable improvement in the respiratory status and a decrease in respiratory distress syndrome in infants who receive prophylactic protein free SS. The meta-analysis supports a decrease in the risk of pneumothorax (typical relative risk 0.67, 95% CI 0.50, 0.90), pulmonary interstitial emphysema (typical relative risk 0.68, 95% CI 0.50, 0.93), and neonatal mortality (typical relative risk 0.70, 95% CI 0.58, 0.85). No differences were seen in the risk of intraventricular hemorrhage, necrotizing enterocolitis, bronchopulmonary dysplasia, retinopathy of prematurity and cerebral palsy. The meta-analysis supports an increase in the risk of patent ductus arteriosus associated with prophylactic SS administration (typical relative risk 1.11, 95% CI 1.00, 1.22), and an increase in the risk of pulmonary hemorrhage (typical relative risk 3.28, 95% CI 1.50, 7.16).

Authors' Conclusions: Prophylactic intratracheal administration of protein free synthetic surfactant to infants at risk of developing respiratory distress syndrome has been demonstrated to improve clinical outcome. Infants who receive prophylactic protein free SS have a decreased risk of pneumothorax, a decreased risk of pulmonary interstitial emphysema, and a decreased risk of neonatal mortality. Infants who receive prophylactic protein free SS have an increased risk of developing patent ductus arteriosus and pulmonary hemorrhage.

Citing Articles

Impaired lung function and associated risk factors in children born prematurely: a systematic review and meta-analysis.

van Boven M, Hutten G, Richardson R, Konigs M, Leemhuis A, Onland W Eur Respir Rev. 2024; 33(174).

PMID: 39384308 PMC: 11462300. DOI: 10.1183/16000617.0114-2024.

Decreasing early invasive mechanical ventilation exposure in preterm infants: a quality improvement initiative.

Welch B, Rose R, Myers J, Drayton Jackson M, Lien I, Barbato A J Perinatol. 2024; 45(1):149-156.

PMID: 39198555 DOI: 10.1038/s41372-024-02098-9.

Strategies for the prevention of bronchopulmonary dysplasia.

Dini G, Ceccarelli S, Celi F Front Pediatr. 2024; 12:1439265.

PMID: 39114855 PMC: 11303306. DOI: 10.3389/fped.2024.1439265.

Non-invasive high-frequency ventilation in newborn infants with respiratory distress.

Abdel-Latif M, Tan O, Fiander M, Osborn D Cochrane Database Syst Rev. 2024; 5:CD012712.

PMID: 38695628 PMC: 11064768. DOI: 10.1002/14651858.CD012712.pub2.

Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome.

Abdel-Latif M, Walker E, Osborn D Cochrane Database Syst Rev. 2024; 1():CD008309.

PMID: 38270182 PMC: 10809312. DOI: 10.1002/14651858.CD008309.pub3.

References

Bose C, CORBET A, Bose G, Lombardy L, Wold D, Donlon D . Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant. J Pediatr. 1990; 117(6):947-53. DOI: 10.1016/s0022-3476(05)80143-x. View

CORBET A, Long W, Schumacher R, Gerdes J, Cotton R . Double-blind developmental evaluation at 1-year corrected age of 597 premature infants with birth weights from 500 to 1350 grams enrolled in three placebo-controlled trials of prophylactic synthetic surfactant. American Exosurf Neonatal Study Group I. J Pediatr. 1995; 126(5 Pt 2):S5-12. DOI: 10.1016/s0022-3476(95)70002-1. View

Soll R . Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2000; (2):CD000511. PMC: 7038705. DOI: 10.1002/14651858.CD000511. View

Phibbs R, Ballard R, Clements J, Heilbron D, Phibbs C, Schlueter M . Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease. Pediatrics. 1991; 88(1):1-9. View

Raju T, Langenberg P . Pulmonary hemorrhage and exogenous surfactant therapy: a metaanalysis. J Pediatr. 1993; 123(4):603-10. DOI: 10.1016/s0022-3476(05)80963-1. View

Milner A, Vyas H, Hopkin I . Effect of exogenous surfactant on total respiratory system compliance. Arch Dis Child. 1984; 59(4):369-71. PMC: 1628669. DOI: 10.1136/adc.59.4.369. View

. Ten centre trial of artificial surfactant (artificial lung expanding compound) in very premature babies. Ten Centre Study Group. Br Med J (Clin Res Ed). 1987; 294(6578):991-6. PMC: 1246154. DOI: 10.1136/bmj.294.6578.991. View

Morley C, Greenough A, Miller N, Bangham A, Pool J, Wood S . Randomized trial of artificial surfactant (ALEC) given at birth to babies from 23 to 34 weeks gestation. Early Hum Dev. 1988; 17(1):41-54. DOI: 10.1016/s0378-3782(88)80056-2. View

Soll R, Blanco F . Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2001; (2):CD000144. DOI: 10.1002/14651858.CD000144. View

10.

Stevenson D, Walther F, Long W, Sell M, Pauly T, Gong A . Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams. The American Exosurf Neonatal Study Group I. J Pediatr. 1992; 120(2 Pt 2):S3-12. DOI: 10.1016/s0022-3476(05)81226-0. View

11.

Wilkinson A, Jenkins P, Jeffrey J . Two controlled trials of dry artificial surfactant: early effects and later outcome in babies with surfactant deficiency. Lancet. 1985; 2(8450):287-91. DOI: 10.1016/s0140-6736(85)90346-0. View

12.

Halliday H, McClure G, Reid M . Growth and development two years after artificial surfactant replacement at birth. Early Hum Dev. 1986; 13(3):323-7. DOI: 10.1016/0378-3782(86)90067-8. View

13.

Yost C, Soll R . Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2000; (2):CD001456. DOI: 10.1002/14651858.CD001456. View

14.

Morley C, Greenough A . Respiratory compliance in premature babies treated with artificial surfactant (ALEC). Arch Dis Child. 1991; 66(4):467-71. PMC: 1792963. DOI: 10.1136/adc.66.4.467. View

15.

KRAYBILL E, Bose C, Corbet A, Asbill D, Edwards K, Long W . Double-blind evaluation of developmental and health status to age 2 years of infants weighing 700 to 1350 grams treated prophylactically at birth with a single dose of synthetic surfactant or air placebo. J Pediatr. 1995; 126(5 Pt 2):S33-42. DOI: 10.1016/s0022-3476(95)70006-4. View

16.

Stevens T, Harrington E, Blennow M, Soll R . Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev. 2007; (4):CD003063. PMC: 8554819. DOI: 10.1002/14651858.CD003063.pub3. View

17.

Seger N, Soll R . Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev. 2009; (2):CD007836. DOI: 10.1002/14651858.CD007836. View

18.

Jobe A . Pulmonary surfactant therapy. N Engl J Med. 1993; 328(12):861-8. DOI: 10.1056/NEJM199303253281208. View

19.

Chu J, Clements J, COTTON E, KLAUS M, SWEET A, TOOLEY W . Neonatal pulmonary ischemia. I. Clinical and physiological studies. Pediatrics. 1967; 40(4):Suppl:709-82. View

20.

Soll R, Morley C . Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2000; (2):CD000510. DOI: 10.1002/14651858.CD000510. View